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kinase II (CaMKII) couples increases in cellular Ca2+
to fundamental responses in excitable cells. CaMKII
was identified over 20 years ago by activation depen-
dence on Ca2+/CaM, but recent evidence shows that
CaMKII activity is also enhanced by pro-oxidant con-
ditions. Here we show that oxidation of paired regu-
latory domain methionine residues sustains CaMKII
activity in the absence of Ca2+/CaM. CaMKII is
activated by angiotensin II (AngII)-induced oxidation,
leading to apoptosis in cardiomyocytes both in vitro
and in vivo. CaMKII oxidation is reversed by methio-
nine sulfoxide reductase A (MsrA), and MsrA/ mice
show exaggerated CaMKII oxidation and myocardial
apoptosis, impaired cardiac function, and increased
mortality after myocardial infarction. Our data dem-
onstrate a dynamic mechanism for CaMKII activation
by oxidation and highlight the critical importance
of oxidation-dependent CaMKII activation to AngII
and ischemic myocardial apoptosis.
INTRODUCTION
The multifunctional calcium/calmodulin (Ca2+/CaM)-dependent
protein kinase II (CaMKII) couples increases in Ca2+ to activation
of ion channels (Grueter et al., 2006), gene transcription (Backs
et al., 2006), and apoptosis (Zhu et al., 2003; Yang et al.,462 Cell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc.2006). CaMKII is activated by enhanced intracellular Ca2+ from
b-adrenergic receptor (bAR) stimulation (Zhang et al., 2005). Ex-
cessive bAR stimulation causes apoptosis by a Ca2+-, CaMKII-,
and caspase-3-dependent pathway (Zhu et al., 2003). TheCaMKII
holoenzyme is assembled from subunits containing three key
domains: the association domain, which directs multimeric as-
sembly, the regulatory domain, which controls enzyme activa-
tion and autoinhibition, and the catalytic domain, which performs
the kinase function of CaMKII. Under resting conditions CaMKII
is inactive, but upon binding Ca2+/CaM, a conformational
change relieves the autoinhibitory effect of the regulatory domain
on the kinase domain, activating the enzyme (Hudmon and
Schulman, 2002; Rosenberg et al., 2005). In the sustained pres-
ence of Ca2+/CaM, CaMKII undergoes intersubunit autophos-
phorylation at T287 (or 286; specific numbering is isoform
dependent), resulting in Ca2+/CaM-independent activity (Hud-
mon and Schulman, 2002). T287 lies within the autoinhibitory
region of CaMKII, and autophosphorylation at T287 produces
Ca2+-autonomous activity by preventing reassociation of the
kinase domain by the autoinhibitory region (Hudmon and Schul-
man, 2002). Interconversion between Ca2+-dependent and
Ca2+-independent forms is a critical property of CaMKII that
allows transformation of a transient Ca2+ stimulus into sustained
physiological or disease-causing activity.
CaMKII activity may also increase in pro-oxidant cellular envi-
ronments (Howe et al., 2004; Zhu et al., 2007), suggesting that
CaMKII has broader functionality than originally envisioned by
connecting ‘‘upstream’’ oxidant stress and Ca2+ signals to
‘‘downstream’’ cellular responses. Based upon the previously
recognized structure-activity response of CaMKII to T287 phos-
phorylation, we hypothesized that oxidation directly modifies the
autoinhibitory motif to confer Ca2+/CaM-independent CaMKII
activity by a mechanism analogous to autophosphorylation.
We identified a direct molecular mechanism for reactive oxygen
species (ROS)-dependent, Ca2+-independent CaMKII activation
by modification of M281/282. Our findings show that direct
activation of CaMKII by ROS engenders Ca2+-autonomous
activity, a clear but previously unrecognized molecular mecha-
nism by which CaMKII can integrate Ca2+ and ROS signals.
Elevated levels of ROS have been measured and contribute to
adverse outcomes after myocardial infarction (Kinugawa et al.,
2000) and in models of heart failure (Maack et al., 2003). Angio-
tensin II (AngII) also increases ROS in heart (Doerries et al., 2007),
while AngII antagonist drugs are a mainstay for reducing mortal-
ity in patients with structural heart disease (Pfeffer et al., 1992,
2003). We hypothesized that CaMKII is a downstream signal
for ischemic and AngII-stimulated apoptosis in heart and that
CaMKII responses were dependent upon the M281/282 activa-
tion mechanism that we identify here. Methionine sulfoxide
reductase A (MsrA) specifically reverses Met oxidation, so we
predicted that MsrA/ mice would show increased CaMKII
oxidation after AngII and ischemic stress. Here we show that
CaMKII inhibition protects against AngII-initiated apoptosis in
heart and that pathological AngII responses recruit CaMKII activ-
ity by M281/282 oxidation in vitro and in vivo. MsrA/ mice
show increased CaMKII oxidation and apoptosis with AngII
and ischemia and increased mortality, greater left ventricular
dilation, and worse in vivo mechanical function after myocardial
infarction, compared to controls. Our data establish CaMKII as
a downstream signal for AngII and ischemic stress and establish
ROS modification of CaMKII at M281/282 as a dynamic mecha-
nism for regulating myocardial responses to common forms of
heart disease.
RESULTS
Oxidation Directly Activates CaMKII
CaMKII is activated by Ca2+/CaM, but autophosphorylation at
T287 sustains catalytic activity after dissociation of Ca2+/CaM
(Figure 1A) because the negatively charged phosphate prevents
reassociation of the catalytic domain and autoinhibitory region
(Hudmon and Schulman, 2002). CaMKII activity may also be
enhanced by pro-oxidant conditions (Zhu et al., 2007); we there-
fore hypothesized that oxidation of the regulatory domain in the
vicinity of T287 could sustain CaMKII catalytic activity by an
analogous mechanism. Exposure of purified CaMKII to H2O2 in
the absence of any pretreatment yielded no discernable CaMKII
activity (Figure 1B). However, exposure to H2O2 after pretreat-
ment with Ca2+/CaM yielded persistent CaMKII activation even
in the presence of EGTA. These data suggest that Ca2+/CaM
binding exposed a key segment of CaMKII for oxidation, and
that oxidation interfered with the interaction of the autoinhibitory
and catalytic domains. Activation of wild-type (WT) CaMKII by
H2O2 was dose dependent (Figure 1C). The concentration of
EGTA used was sufficient to block CaMKII activity without the
addition of H2O2 (Figure 1B), suggesting that activity observed
in the pro-oxidant condition was independent of sustained
Ca2+/CaM binding.Pretreatment with Ca2+/CaM was also necessary for auto-
phosphorylation-dependent CaMKII activation, indicating that
autophosphorylation and oxidation of CaMKII occur by parallel
mechanisms. CaMKII bearing a T287A substitution underwent
normal Ca2+/CaM-dependent activation but did not maintain
persistent Ca2+-independent activity in the presence of ATP
(Figure 1D). However, the T287A mutant was activated by H2O2
(Figure 1C), and theextent of this activationwasstatistically indis-
tinguishable at all but the highest concentration of H2O2 tested
(1mM).We interpret theseobservationsasevidence thatactivation
of CaMKII by ROS and autophosphorylation occur by a similar
mechanism, but by independent modifications to nearby sites.
Activation of the kinaseby eithermechanism requires theenzyme
to be initially ‘‘opened’’ by Ca2+/CaM to allow access to the auto-
inhibitory domain for oxidation or autophosphorylation (Figures
1Aand1E). Either of thesemodifications can prevent subsequent
interaction of the autoinhibitory region with the catalytic domain,
providing for sustained Ca2+-independent activation of CaMKII.
Consistent with these ideas, direct measurements of intrinsic
fluorescence revealed that autophosphorylation and oxidation
of CaMKII independently induce similar conformational changes
in CaMKII (Figure S1 available online).
Proteomic analysis of the synthetic peptide that contains the
281/282 methionine residues was used to probe for oxidative
modification upon treatment with H2O2. We observed a clear
decrease in the unoxidized form coupled with an increase in
the various oxidized forms of this peptide based on the chro-
matographic traces and on the change in the number of ob-
served spectra (Figure S2). In addition to the synthetic peptide,
we analyzed the peptide containing the 281/282 methionine res-
idues after treatment of the whole protein with H2O2 followed by
trypsin cleavage. We were able to determine the relative change
in oxidation of this peptide upon hydrogen peroxide treatment
(Tables S1 and S2). The MS/MS spectra of the oxidized forms
of the peptide were identical to those from the synthetic peptide,
verifying that the oxidized peptide was correctly identified.
Given these observations and the recognized susceptibility of
methionine residues to oxidation (Hoshi and Heinemann, 2001),
we made methionine to valine mutations for the paired residues
(M281/282V)and foranothermethionine (M308V) in theCaM-bind-
ing region. These mutants were exposed to H2O2 and assayed for
activity in the presence of EGTA (Figure 1C). The H2O2-dependent
activation of CaMKII was preserved in the M308V mutant. How-
ever, oxidation-dependent CaMKII activity was completely abol-
ished in the M281/282V and M281/282/308V mutants. Our data,
obtained in cell-free assay conditions, point to direct oxidation of
the M281/282 pair as the primary H2O2-dependent activation
pathway for CaMKII. Importantly, all the methionine to valine
mutants showed a normal activity response to autophosphoryla-
tion (Figure 1D), further supporting the concept that Ca2+-autono-
mous CaMKII activation by ROS or T287 autophosphorylation are
independent events. While the paired methionine motif is con-
served in theb,g, and d isoformsofCaMKII, the neuronala isoform
substitutes a cysteine residue for the first methionine of the pair
(position 280 in CaMKIIa). The side chain of cysteine is also sus-
ceptible to oxidation. We generated a M281C mutant of CaMKIId
to mimic the substitution in CaMKIIa. Additionally, we generated
and purified CaMKIIa. Both the M281C CaMKIId mutant and theCell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc. 463
Figure 1. CaMKII Is Activated by ROS
(A) General structure of a subunit from the multimeric holoenzyme CaMKII and mechanism of CaMKII activation by autophosphorylation. The amino acid
sequence of the regulatory domain is highlighted to show the autoinhibitory (AI) and calmodulin-binding (CaM-B) regions. Yellow symbols represent CaM.
Pretreatment with Ca2+/CaM (1) followed by phosphorylation at T287 (2) yields persistent activity even after the removal of Ca2+/CaM (3).
(B) Kinase assays were performed after three distinct treatment steps: (1) ±Ca2+/CaM, (2) ±H2O2 or ATP, and (3) ± EGTA (n = 6 assays/group, *p < 0.05 versus
WT no treatment).
(C) CaMKII is activated by H2O2 in a dose-dependent manner after pretreatment with Ca
2+/CaM. Oxidation-dependent CaMKII activity is ablated in M281/282V
mutants (n = 6 assays/group, *p < 0.05 versus WT no treatment).
(D) M281/282V mutants have normal Ca2+/CaM-dependent and T287-autophosphorylation-dependent activation (n = 6 assays/group, *p < 0.05 versus WT no
treatment).
(E) Proposed mechanism for activation of CaMKII by oxidation. After initial activation of the holoenzyme by Ca2+/CaM (1), oxidation at M281/282 (2) blocks
reassociation of the catalytic domain, yielding persistent CaMKII activity (3).
Error bars represent SEM.purified CaMKIIa were activated by H2O2, indicating that the cys-
teine substitution seen in CaMKIIa also supports ROS-dependent
activation (Figure 1C). To further elucidate the role of M281 and
M282 in ROS-dependent activation, these sites were individually
mutated (Figure S3). The M282V mutation completely ablated464 Cell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc.oxidation-dependentactivation,while theM281Vmutationpartially
reduced activation by 65%, indicating that a single oxidation event
within the regulatory domain is insufficient to activate CaMKII.
Autophosphorylation at T287 dramatically increases the bind-
ing affinity of CaMKII for CaM, a phenomenon known as ‘‘CaM
trapping’’ (Meyer et al., 1992). In the absence of ATP the Ca2+/
CaM/CaMKII complex was very rapidly dissociated following ad-
dition of EGTA, independent of the redox state, as measured by
fluorescence anisotropy of dansylatedCaM (Figure S4A). CaMKII
exposure to H2O2 for 10min inducedCa
2+/CaM-independent ac-
tivity (as in Figure 1B) but also failed to induce CaM trapping (not
shown). These observations indicate that under normal experi-
mental conditions, oxidation of CaMKII is not sufficient to induce
CaMtrapping.DissociationofCa2+/CaMfromautophosporylated
CaMKII and CaM was significantly slower than from nonphos-
phorylated enzyme, consistentwithCaM trapping. However, pre-
treatment withH2O2 prior to EGTAhad no significant effect on the
dissociation kinetics. Thus, oxidation of CaM or CaMKII does not
preventorenhanceCaMtrappingbyautophosphorylatedCaMKII.
CaM trapping is reduced by phosphorylation of T306/307 (Col-
bran, 1993), so we investigated whether oxidation of M308might
prevent CaM trapping by a parallel mechanism. We did observe
a significant slowing of dissociation of the CaM/CaMKII complex
after H2O2 treatment of the M308 mutant (Figures S4B and S4C).
These data suggest that the absence of CaM trapping during ox-
idation is partly due to M308.
It seemed possible that conditions capable of oxidizing methi-
onine residues would also oxidize unprotected cysteine resi-
dues. Although mutation of methionine residues at 281 and
282 was sufficient to completely ablate ROS-dependent activa-
tion of CaMKII, we created a C290V mutant to determine
whether this cysteine residue within the CaMKII regulatory
domain could also play a role. Both the Ca2+/CaM-dependent
activity and the ROS-dependent activity of the C290V mutant
were indistinguishable from that with WT CaMKII (Figure S4D).
Our finding that oxidation of paired amino acids (M281/282 in
CaMKIId) was required for activation by H2O2 supports a view
that oxidation of a lone residue is insufficient to confer Ca2+/
CaM-autonomous CaMKII activity. In order to comprehensively
test the potential role of all accessible cysteines in contributing
to oxidation-dependent CaMKII activity we measured CaMKII
activity responses to H2O2 in the presence of iodoacetic acid,
a reagent that blocks oxidation of unprotected cysteine residues
(Zangerle et al., 1992). Cysteine-protected CaMKIId showed
equivalent H2O2 activity responses compared to CaMKIId
without iodoacetic acid (Figure S2D). We used an established
colorometric assay to quantify the available cysteine residues
and verify that cysteine protection by iodoacetic acid was effec-
tive. Our results confirmed that most or all of the 11 cysteines in
CaMKIId were accessible to the Ellman’s reagent after Ca2+/
CaM binding, while treatment with iodoacetic acid blocked the
accessibility of cysteine residues to biochemical modification
(data not shown). Taken together, these findings demonstrate
that oxidative activation of CaMKIId is independent of cysteines.
Oxidation of CaMKII Occurs In Vivo
Wedevelopedan immuneserumagainstoxidizedM281/282 tode-
tect ROS effects on CaMKII in vivo. We validated the fidelity of the
antiserumusingpurifiedCaMKIIproteinby immunoblottingagainst
WT CaMKII and the M281/282V mutant in control conditions and
after treatment with H2O2 or Ca
2+/CaM/ATP. Blots were also as-
sayed with a phospho- and site-specific antibody against T287
(p-287). WT CaMKII exposed to H2O2 after pretreatment withCa2+/CaM showed significant reactivity to our oxidized M281/
282 antiserum, but untreated and T287-phosphorylated CaMKII
samples were not recognized by our antiserum (Figure 2A). The
M281/282Vmutant hadminimal reactivity to our antiserumamong
the three treatments. These findings demonstrated that phospho-
T287 and oxidized M281/282 were immunologically distinct sites.
We performed additional immunoblots in which oxidized CaMKII
was probed with the antiserum along with increasing concentra-
tions of the peptide antigen (Figure 2B). Band intensity decreased
with increasing peptide concentration, indicating that the immune
serum was specific for oxidized CaMKII.
To determine the role of CaMKII oxidation in apoptosis,
mice were treated with saline, AngII, or isoproterenol (Iso) for
1 week, and transverse heart sections from these mice were
probed for the production of oxidized CaMKII in vivo. WT mice
treated with AngII produced more oxidized CaMKII than those
treated with saline or Iso (Figure 2C). Total CaMKII immunoreac-
tivity remained constant regardless of treatment. Conversely,
mice lacking a critical subunit of NADPH oxidase (p47/) did
not show increased levels of oxidized CaMKII in response to An-
gII. The p47/mice did not assemble the ROS-producing com-
plex NADPH oxidase (Munzel and Keaney, 2001), the main
source of ROS due to AngII stimulation in many cell types (Lyle
and Griendling, 2006). Heart sections from WT mice showed
increased staining for T287-phosphorylated CaMKII after AngII
treatment, while p47/mice were unaffected (Figure S5). Other
studies have suggested that protein phosphatase activity is de-
creased by pro-oxidant conditions (Howe et al., 2004), indicating
the possibility of coordinate activation of CaMKII both by direct
oxidation at the Met281/282 sites and by phosphatase inactiva-
tion leading to increased phosphorylation at the T287 site.
We also homogenized hearts from mice treated with saline,
AngII, or Iso, and whole heart lysates were analyzed by immuno-
blot for oxidized CaMKII. While total CaMKII was not significantly
different among the three treatment groups, heart lysates from
mice treated with AngII showed significantly increased oxidized
CaMKII levels (Figure 2D). Taken together, these findings
demonstrate that oxidation of CaMKII occurs in vivo, and that
elevated levels of AngII increase CaMKII oxidation at M281/
282 compared to saline or Iso.
AngII Triggers ROS Production and CaMKII-Dependent
Apoptosis in Cardiomyocytes
Given our results, we hypothesized that cells deficient in ROS
production or CaMKII activity would be resistant to AngII-medi-
ated apoptosis. We treated cardiomyocytes from mice that
express an inhibitory peptide against CaMKII (AC3-I, Zhang
et al., 2005) with 100 nM AngII for 24 hr in parallel with isolated
cardiomyocytes fromWTandp47/mice. AngII caused a signif-
icant increase in the percent of TUNEL-positive nuclei inWT cells
but had no significant effect in p47/ or AC3-I cardiomyocytes
(Figure 3A). Activity assays for caspase-3, a downstream target
enzyme in the CaMKII apoptotic signaling pathway in heart,
recapitulated the results from the TUNEL assay (Figure 3B).
Importantly, direct addition of ROS in the form of H2O2 caused
significant apoptosis in p47/ cells, demonstrating that their re-
sistance to AngII-induced apoptosis is a result of impaired ability
to produce ROS rather than a lack of sensitivity to ROS. TheCell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc. 465
Figure 2. AngII Induces Oxidation of CaMKII In Vivo
(A) Immunoblot ofWTCaMKII andM281/282Vmutant after no treatment, oxidation, or autophosphorylation probedwith antibodies against total, autophosphory-
lated (p-T287), or oxidized CaMKII. Summary data shows relative band intensity using the oxidized CaMKII antibody (n = 3 trials/group, *p < 0.05 versus band
intensity of WT CaMKII treated with H2O2).
(B) Immunoblot and summary data of oxidized WT CaMKII probed with antiserum against oxidized M281/282 with increasing ratios of oxidized antigen peptide
(n = 3 trials/group, *p < 0.05 versus band intensity with no peptide).
(C) Immunofluorescent staining of heart sections from mice treated with saline, AngII, or Iso and probed for oxidized or total CaMKII. Red staining is positive for
oxidized or total CaMKII and blue staining is for nuclei. Calibration bars are 100 microns.
(D) Immunoblot and summary data of heart lysates frommice treated with saline (Sal), Iso, or AngII probed with antibodies against total CaMKII, oxidized CaMKII,
or actin (n = 3 hearts/group, *p < 0.05 versus band intensity of saline treatment).
Error bars represent SEM.apoptotic effect of H2O2 in AC3-I cells was blunted by more than
half compared to WT or p47/ cells (Figure 3A), indicating
the critical importance of CaMKII activation to ROS- and
Iso-dependent apoptosis.
In order to validate the connection between AngII and ROS in
our experimental model, we treated isolated cardiomyocytes
fromWT and p47/mice with 100 nM AngII and monitored pro-
duction of ROSby imaging DHE, a fluorescent reporter for super-
oxide and hydrogen peroxide (Figure 3C). We also incubatedWT
cardiomyocytes with fura-2 AM, a cell-permeant calcium indica-
tor, to observe changes in intracellular Ca2+ ([Ca2+]i). Treatment
with AngII caused a significant increase in ROS production in466 Cell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc.WT but not in p47/ cardiomyocytes (Figure 3D). On the other
hand, increases in [Ca2+]i were significantly less after AngII com-
pared to Iso treatment (Figures 3E and 3F) for cardiomyocytes
from both WT and p47/ mice. These data show that AngII
signaling predominantly increases ROS, while Iso predominantly
increases [Ca2+]i under our experimental conditions.
CaMKII Knockdown Prevents
AngII- and Iso-Induced Apoptosis
In order to further test the role of CaMKII and specifically define
the effects of M281/282 on myocardial apoptosis, we used
a knockdown and replacement strategy in cultured neonatal
Figure 3. AngII Increases ROS Production and Apoptosis by a CaMKII-Dependent Pathway in Cardiomyocytes
(A) Percent of total isolated cardiomyocytes positive for TUNEL staining after treatment with saline, AngII, Iso, or H2O2 (n = 6 hearts/group, *p < 0.05 versus WT
with saline).
(B) Caspase-3 activity induced by saline, AngII, or Iso normalized to WT cells treated with saline (n = 3 hearts/group, *p < 0.05 versus WT with saline).
(C) DHE-stained cardiomyocytes after treatment with 100 nM AngII or Iso. Red coloration indicates presence of ROS above control cells. Scale bars equal 50 mm.
(D) Percent of total cells positive for DHE staining above control (n = 3 assays/group, *p < 0.05 versus WT saline).
(E) Example traces of intracellular calcium concentration of cultured WT cardiomyocytes treated with 100 nM AngII (red symbols) or Iso (blue symbols) measured
by real-time calcium imaging. The arrow indicates addition of AngII or Iso.
(F) Peak intracellular Ca2+ concentration in response to either AngII or Iso for WT or p47/ cells (n = 3 trials/group, NS = not statistically different).
Error bars represent SEM.cardiomyocytes. Rat cardiomyocytes were cultured and treated
with shRNA-encoding lentivirus against rat CaMKIId. After 48 hr
CaMKII expression was significantly reduced, as measured by
immunoblot and activity assays (Figure 4A). Cells were then
transduced with lentivirus encoding shRNA-resistant WT or
M281/282V mutant CaMKII. Control cells were transduced withGFP-encoding lentivirus. After 48 hr, cells transduced with
CaMKII rescue constructs showed significant recovery of
CaMKII expression compared to control cells. Addition of Ca2+/
CaM to lysates from cells transduced with either CaMKII-encod-
ing virus had similar total activity to native cells. However, H2O2-
induced activity was only rescued in cells expressing the WTCell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc. 467
Figure 4. AngII-Induced Apoptosis Is Blocked by CaMKII Silencing
(A) Representative immunoblot with anti-CaMKII to measure protein expression after treatment with shRNA and shRNA-resistant rescue constructs. Immunoblot
against actin was used as a loading control (not shown). Middle panel shows summary data of CaMKII expression relative to untreated cells (n = 3 experiments/
group, *p < 0.05 versus no treatment). Bottom panel shows summary data for CaMKII activity assays of lysates (n = 3 experiments/group, *p < 0.05 versus total
activity with no treatment, yp < 0.05 versus ROS-dependent activity with no treatment). Only the WT CaMKII construct was able to reconstitute both Ca2+/
CaM- and ROS-dependent activity observed in untreated cells.
(B) Immunostaining and (C) summary data from isolated rat cardiomyocytes transduced with shRNA against CaMKII followed by rescue with WT CaMKII, M281/
282V, or GFP control are shown. Immunostaining shows total nuclei (DAPI) and DNA nicking (TUNEL) consistent with apoptosis. Scale bars equal 100 mm.
Summary data show percent of total nuclei with positive TUNEL staining (n = 6 hearts/group, *p < 0.05 versus GFP with AngII).
Error bars represent SEM.CaMKII construct. These cellular studies support our earlier
finding with molecular CaMKII (Figure 1) by showing that oxida-
tion of M281/282 is critical for ROS-triggered CaMKII activity. In
addition, this strategy created cardiomyocytes that express468 Cell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc.ROS-resistant CaMKII, providing a system for investigating
ROS- and CaMKII-dependent apoptosis.
Cardiomyocytes treated with shRNAs/CaMKIId-encoding len-
tivirus were exposed to saline, AngII, or Iso as above (Figure 4B).
The apoptotic response to AngII and Iso was significantly atten-
uated in CaMKII knockdown cells compared to myocytes
without shRNA. Moreover, expression of shRNA-resistant WT
CaMKII fully rescued apoptotic responses to both agonists
(Figure 4C). In contrast, expression of the ROS-resistant M281/
282V CaMKII mutant rescued the apoptotic response to Iso
but, importantly, failed to rescue the apoptotic response to AngII
after 24 hr (Figure 4C). Cells expressing the M281/282V CaMKII
remained susceptible to Iso-induced apoptosis (Figures 4B and
4C), indicating that elimination of these residues does not affect
activation of CaMKII by catecholamine stimulation. These cellu-
lar studies are performed in a complex biological environment
compared to studies with isolated CaMKII but nevertheless sup-
port the concept that direct oxidation of CaMKII by AngII is suf-
ficient to confer enhanced CaMKII activity and trigger apoptosis.
ROS Production and CaMKII Activity Are Critical
for AngII-Mediated Cardiac Apoptosis In Vivo
Intracellular ROS levels increase dramatically in models of struc-
tural heart disease (Hare, 2001), particularly those initiated by
AngII (Tojo et al., 2002). Stimulation by AngII leads to activation
of the NADPH oxidase complex, increasing intracellular super-
oxide and hydrogen peroxide levels. To establish an in vivo
context for our previous findings and to test the role of CaMKII
in AngII-stimulated cardiac apoptosis, p47/, AC3-I, and WT
Figure 5. AngII Causes Cardiac Apoptosis In Vivo
via a ROS- and CaMKII-Mediated Pathway
(A) Immunostaining ofmouse heart sections for total nuclei
(DAPI) and nuclear damage (TUNEL) consistent with apo-
ptosis.WT,p47/, andAC3-Imicewere treatedwith Ang II
(3 mg/kg/day) or Iso (30 mg/kg/day) for 7 days. Scale bars
equal 100 mm.
(B) Percent of total nuclei that showed positive TUNEL
staining (n = 3 hearts/group, *p < 0.05 versus WT with
saline).
Error bars represent SEM.
mice were treated with saline, AngII, or Iso for
1 week. Transverse heart sections from these
mice were stained for evidence of apoptosis. Af-
ter 1 week WT mice treated with either AngII or
Iso showed significant cardiac apoptosis, as de-
termined by TUNEL staining of heart sections
(Figure 5). The p47/mice had no significant in-
crease in cardiac apoptosis after treatment with
AngII, most likely because these mice were un-
able to produce ROS in response to AngII stim-
ulation (Figure 3D). However, the p47/ mice
showed a preserved apoptotic response to
Iso, suggesting that Iso-induced apoptosis oc-
curs independently of oxidative stress gener-
ated by NADPH oxidase in vivo under these
conditions. In contrast, the AC3-I mice with
CaMKII inhibition were resistant to apoptosis in-
duced by either AngII or Iso, indicating that
CaMKII is a necessary signal element for apoptosis initiated by
AngII or Iso in vivo.
Increased CaMKII Oxidation, Apoptosis, Cardiac
Dysfunction, and Death inMsrA/ Mice
Methionine oxidation is specifically reversed by MsrA (Weiss-
bach et al., 2002), so we hypothesized thatMsrA/mice would
show enhanced vulnerability to AngII-mediated CaMKII oxida-
tion and apoptosis. In order to test this idea we implanted
MsrA/ and WT control mice with AngII- or saline-eluting os-
motic minipumps. Hearts from MsrA/ mice treated with AngII
in vivo showed significantly more CaMKII oxidation (Figures 6A
and 6B) and increased TUNEL staining (Figure 6C) compared
to saline-treated MsrA/ mice and to saline- or AngII-treated
control hearts. The increased CaMKII oxidation by AngII in
MsrA/ hearts showed that CaMKII oxidation is dynamically
regulated by MsrA in myocardium in vivo and suggested that
MsrA/ mice would be more vulnerable to severe myocardial
stress due to increased methionine oxidation. Myocardial infarc-
tion is the most common cause of sudden cardiac death and
heart failure in patients, and p47/ (Doerries et al., 2007) and
AC3-I mice (Zhang et al., 2005) are protected from left ventricular
dilation and dysfunction after myocardial infarction surgery, sug-
gesting that ROS activation of CaMKII may be important in
myocardial infarction. In order to test if CaMKII oxidation andCell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc. 469
apoptosis were regulated by NADPH oxidase and MsrA in the
setting of myocardial infarction, we subjected MsrA/, p47/,
and WT mice to myocardial infarction surgery. MsrA/ mice
showed significantly more CaMKII oxidation (Figures 7A and
7B) and myocardial apoptosis (Figure 7C) compared to WT
and p47/ mice. These data indicate that CaMKII oxidation is
dynamically regulated by NADPH oxidase and MsrA in the
setting of myocardial infarction. We performed myocardial
infarction surgery on a larger cohort of MsrA/ and WT control
mice to determine if increased CaMKII oxidation and apoptosis
in MsrA/ mice translated into poorer functional outcomes.
Figure 6. MsrA/ Mice Have Increased Susceptibility to AngII-
Mediated Apoptosis
(A) Immunofluorescent staining of heart sections from WT and MsrA/ mice
treated with AngII and probed for oxidized or total CaMKII. Red staining is pos-
itive for oxidized or total CaMKII and blue staining is for nuclei. Calibration bars
are 100 microns.
(B) Quantification of average staining intensity for AngII-treated hearts, relative
to WT (n = 3 hearts/group, *p < 0.05 versus WT with AngII).
(C) Summary data for TUNEL staining of heart sections from WT andMsrA/
mice treated with saline or AngII (n = 5 hearts/group, *p < 0.05 versus WT with
saline).
Error bars represent SEM.470 Cell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc.MsrA/ mice were significantly more likely to die after surgery
compared to WT controls (Figure 7D, p = 0.0015) and exhibited
significantly greater left ventricular dilation (Figure 7E) and
impaired systolic function (Figure 7F) compared to controls,
demonstrating that methionine oxidation increases the patho-
logical impact of myocardial infarction in vivo.
DISCUSSION
CaMKII was first identified by its dependence on Ca2+/CaM for
activation (Schulman and Greengard, 1978). Later it was recog-
nized that autophosphorylation at T287 modified the enzyme so
that activity persisted even in the absence of elevated Ca2+/CaM
(Saitoh and Schwartz, 1985; Lou et al., 1986; Patton et al., 1990).
Our findings show that oxidation ofM281/282 is a distinct molec-
ular event but with similar consequences to Thr287 autophos-
phorylation for sustaining Ca2+/CaM-independent activity and
thus reveal another dimension to CAMKII signaling. Oxidative
activation likely is important in all known CaMKII isoforms and
relies upon paired, oxidation-susceptible residues (MM in b, g,
and d). Because of the ability of CaMKII to transition between
Ca2+/CaM-dependent and Ca2+/CaM-independent species,
CaMKII is considered a ‘‘memory molecule’’ for the history of
intracellular Ca2+ elevation. ROS facilitation of Ca2+/CaMCaMKII
activity suggests that the ability of CaMKII to respond to Ca2+
elevation is enhanced in pro-oxidant conditions. Because
increased CaMKII activity and oxidative stress are implicated
in a wide variety of physiological and disease processes, our
findings have potentially broad implications for improved under-
standing of connections between ROS and Ca2+ in multiple cell
types.
CaMKII is initially activated by Ca2+/CaM binding, which
blocks the autoinhibitory association between the regulatory
and catalytic domains. Phosphorylation of T287 blocks the reas-
sociation of the regulatory and catalytic domains, conferring
Ca2+/CaM-independent activity on the enzyme (Hudmon and
Schulman, 2002). In this study, we discovered a mechanism
for CaMKII activation by oxidation of M281/282. As is the case
for T287 autophosphorylation, activating oxidation appears to
require that the regulatory domain is first exposed by Ca2+/
CaM binding, whereupon oxidation at M281/282 leads to persis-
tent Ca2+/CaM-autonomous activation of CaMKII. Oxidation of
methionine residues changes both the charge and flexibility of
their side chains (Hoshi and Heinemann, 2001), apparently lead-
ing to steric blockage of reassociation between the regulatory
and catalytic domains. Surprisingly, cysteine residues, a com-
mon target for oxidative regulation (Barford, 2004), do not
appear to play any role in oxidative activation of CaMKIId (or
by inference CaMKIIb or g). The regulatory domains of all CaMKII
isoforms contain a single cysteine (C290 in CaMKIId), but oxida-
tion of this unpaired cysteine is insufficient to activate CaMKIId.
Our data are alignedwith the concept that Ca2+/CaM-dependent
exposure of the regulatory domain sets up the CaMKII molecule
for subsequent modifications that confer persistent, Ca2+-inde-
pendent activity.
Our findings identified a previously unrecognized mechanism
of enhancing CaMKII by direct methionine oxidation, but oxida-
tion may affect activity of kinases by multiple mechanisms.
Pro-oxidant conditions can modify the activity levels of protein
kinases by direct and indirect mechanisms. For example, direct
thiol oxidation within the ATP-binding pocket inhibits MEK
kinase 1 activity (Cross and Templeton, 2004). Oxidative stress
can induce activation of ERK1/2 (Engers et al., 2006), while
oxidation-dependent inactivation of protein phosphatases
(Tonks, 2006) and activation of upstream kinase kinases, such
as IKK-b (Reynaert et al., 2006) can indirectly lead to increased
kinase activity. The present findings that AngII increases both
CaMKII oxidation and autophosphorylation suggest that ROS
inhibition of phosphatases further enhances CaMKII activity
responses to oxidant stress in vivo.
Autophosphorylation at T287 is reversed by phosphatase
activity (Zhabotinsky, 2000; Hudmon and Schulman, 2002).
Because phosphorylation is a readily reversible process, activa-
tion by autophosphorylation represents a tunable regulatory
mechanism for CaMKII. Oxidation of methionine residues is
also a reversible biochemical modification, and the presence of
methionine residues can confer functional sensitivity to oxidative
stress (Santarelli et al., 2006). Msr reduces the side chain of
Figure 7. Mice Lacking MsrA Have
Increased CaMKII Oxidation, Apoptosis,
Reduced Survival, and Impaired Heart
Function after Myocardial Infarction
(A) Immunostaining and (B) stain intensity quantifi-
cation of oxidized CaMKII in heart sections from
WT, p47/, and MsrA/ mice post-MI (n = 3
hearts/group, *p < 0.05 versus WT).
(C) Summary data for TUNEL staining of heart sec-
tions fromWT, p47/, andMsrA/mice post-MI
(n = 3 hearts/group, *p < 0.05 versus WT).
(D) Mortality is significantly increased post-MI in
MsrA/mice compared toWT controls. Numbers
in bars represent post-MI deaths/total number of
mice receiving MI. Post-MI left ventricular dilation
(E) and function (F) were compromised in surviving
MsrA/ mice compared to WT controls 3 weeks
after surgery (n = 17 hearts/group for WT, n = 9
hearts/group for MsrA/).
Error bars represent SEM.
methionine to its native state (Kryukov
et al., 2002) and is therefore a critical
defense mechanism against cellular
damage by oxidative stress. Mutant Dro-
sophila overexpressing Msr have longer
life spans (Ruan et al., 2002), while
MsrA/ mice show increased mortality
in response to oxidant-induced aging
(Moskovitz et al., 2001). The importance
of MsrA in various biological systems
suggests that reversible oxidation of me-
thionine residues could complement
a Thr287 phosphorylation/dephosphory-
lation cycle by serving as a ROS-respon-
sive regulatory mechanism for dynami-
cally titering CaMKII activity. Our studies
show that MsrA is essential for reversing
CaMKII oxidation in myocardium in vivo
and that increased methionine oxidation worsens important
clinical outcomes after myocardial infarction.
Structural heart disease is one of the largest public health
problems in the developed world (Jessup and Brozena, 2003).
AngII and bAR receptor antagonist drugs have significantly re-
duced mortality in patients with structural heart disease
(MERIT-HF Study Group, 1999; Pfeffer et al., 2003) and repre-
sent a remarkable success story for translating basic scientific
understanding of cellular signaling into effective treatments for
human disease. Increased cardiomyocyte apoptosis appears
to be an important feature of advanced structural heart disease
(Olivetti et al., 1997). CaMKII is activated downstream to bAR re-
ceptor stimulation (Zhang et al., 2005) by increased [Ca2+i] (Zhu
et al., 2003). CaMKII inhibition reduces apoptosis (Zhu et al.,
2003; Yang et al., 2006) and improves mortality (Khoo et al.,
2006) in structural heart disease models. These findings have
contributed to a growing perception that CaMKII inhibition may
be a novel therapeutic strategy for treating heart failure and
arrhythmias (Bers, 2005). Our data reveal the importance of
M281/282 oxidation for CaMKII activation and thereby provideCell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc. 471
a molecular mechanism for understanding the effects of AngII in
cardiomyocytes and in structural heart disease. Our present
findings appear to increase the potential importance of CaMKII
in structural heart disease by positioning CaMKII as a critical
downstream nodal signal for enhancing cardiomyocyte death
in response to excessive catecholamines, AngII andROS.CaMKII
has proven to be a remarkably versatile signaling molecule, and
the recently recognized role of ROS in activating CaMKII pro-
vides a way of understanding the potential for oxidant stress to
engage physiological and disease pathways in excitable cells.
EXPERIMENTAL PROCEDURES
Mouse Models
Mice lacking the p47 gene (p47/) were purchased from Jackson Labs. Mice
lacking the protein MsrA (MsrA/) were supplied by NIH (Bethesda, MD,
USA). Mice with genetic CaMKII inhibition (AC3-I) were generated by us as
previously described (Zhang et al., 2005).
CaMKII Activity Assays and Protein Analysis
Mutant CaMKII cDNAs were generated using a QuikChange site-directed
mutagenesis kit (Stratagene). CaMKIId (GenBank #NP_001020609) was gen-
erated using the Bac-to-Bac baculovirus system (Invitrogen) and purified on
a calmodulin-agarose column. For CaMKII activity assays, purified CaMKII
was pretreated with 200 mMCaCl2 and 1 mMCaM on ice for 1 min. The protein
was then exposed to ATP, H2O2, or water at the described concentrations for
10 min. Samples exposed to ATP or H2O2 were then treated with 10 mMEGTA
for 10 min. CaMKII activity was measured as a function of 32P-ATP incorpora-
tion into a synthetic substrate (syntide-2) at 30C, as previously described (Wu
et al., 2002).
Oxidized M281/282 Immune Serum Production
and Immune Staining
Antiserum to the oxidized CaMKII regulatory domain peptide was generated
by Epitomics, Inc. Commercial antibodies were used for blots and immunos-
taining for total (Stressgen Biotechnologies) and phosphorylated (Santa
Cruz) CaMKII.
Detection of ROS
Changes in ROS levels in cultured primary cardiac myocytes after agonist
stimulation were measured using the fluorgenic probe dihydroethidium
(DHE, 5 mM, Molecular Probes), as previously described (Zimmerman et al.,
2004). DHE fluorescent images were acquired using confocal microscopy
(Zeiss LSM510).
Intracellular Calcium Concentration Measurements
Intracellular calcium concentration was assessed by Fura-2 fluorescence ratio
imaging using amicroscopic digital imaging system (Photon Technology Inter-
national), as described previously (Sharma et al., 1995).
Fluorescence Measurements
Spectra were collected at 30C using a Fluorolog 3 (Jobin Yvon, Horiba) spec-
trofluorometer. For intrinsic fluorescence shift experiments, excitation wave-
length was 270 nm. Emission spectra were generated at 1 nm increments
from 280 nm to 400 nm. Background traces were subtracted from CaMKII
spectra to eliminate the contribution from intrinsic fluorescence of CaM. For
fluorescence anisotropy experiments, baseline traces of 100 nM dansylated
CaM in 15 mM HEPES buffer (pH 7.2) were measured at baseline and after
the addition of 200 mM CaCl2 at 60 s. At 180 s, 100 nM purified CaMKII was
added to the CaM solution. For some trials, CaMKII became phosphorylated
by the addition of 10 mM ATP. One hundred microliters H2O2 or an equivalent
volume of buffer was added at 250 s. Finally, addition of 10 mM EGTA at 300 s
was used to remove free calcium from the solution, uncoupling CaM/CaMKII
binding.472 Cell 133, 462–474, May 2, 2008 ª2008 Elsevier Inc.Cardiomyocyte TUNEL Immunostaining
Myocyte isolations from neonatal mouse or rat pups were modified from
previously described methods (Mohler et al., 2007). To ensure that pure
populations of cardiomyocytes were obtained, cultures were immunolabeled
with a-actinin Ig (cardiomyocyte-specific marker). Only cultures with >90%
cardiomyocytes were used in experiments (see Figure S6). Lentiviral treat-
ments (shRNA, rescue constructs) and apoptosis-inducing agents (Iso, AngII)
were used for 24 hr. Cells were fixed in 4% paraformaldehyde, permeabilized
in 0.1% Triton X-100 and sodium citrate, and stained using In Situ cell death
detection kits, TMR Red (Roche). TUNEL stain assays were interpreted as
previously described (Yang et al., 2006). Nuclei were costained with DAPI.
Investigators were blinded to the genetic identity and treatment of the mice
in all studies.
CaMKII cDNA, shRNA, and Virus Generation
See Supplemental Data for sequences and methods.
Heart Section TUNEL Immunostaining
Minipumps containing saline or AngII (3 mg/kg/day) were inserted or daily
injections of Iso (30 mg/kg/day, intraperitoneal) were given for 7 days. Animals
were then sacrificed and the heart was removed, fixed, and embedded in par-
affin. To confirm specific labeling of cardiomyocytes, heart sections were
labeled with a-actinin Ig (cardiomyocyte-specific marker). Only sections with
>90% cardiomyocytes were used in experiments (see Figure S7). TUNEL
staining was performed using In Situ cell death detection kits, TMR Red
(Roche). Nuclei were costained with DAPI. An investigator blinded to the iden-
tity and treatment of the mice counted the number of total and TUNEL-positive
cells in each image.
Other sections were treated with either a general CaMKII antibody or
oxidized CaMKII antiserum. Nuclei were costained with DAPI. Identity of
cardiomyocytes was confirmed by costain with an antibody against a-actinin.
Images were quantified for relative staining intensity using Image J (NIH). Both
the investigators and technical personnel assigned to immunostaining and
quantification were blinded to the genetic identity and treatment of the mice
in all studies.
Myocardial Infarction and Echocardiography
Mice were anesthetized with ketamine/xylazine (87.5/12.5 mg/kg, respec-
tively), and the left anterior descending (LAD) branch of the coronary artery
was ligated using 8-0 ethilon suture (Ethicon) along the anterolateral border
of the heart as close to the left atrial appendage as possible. Successful liga-
tion of the artery is confirmed by blanching of the myocardium. Transthoracic
echocardiogramswere recorded in conscious sedatedmice as described pre-
viously (Weiss et al., 2006), using a 15 MHz probe connected to a Sonos 5500
imager (PhillipsMedical Systems, Bothell, WA, USA). Imageswere acquired by
an operator blinded to mouse genotype.
Statistical Analysis
Statistical significance for mortality study was determined by chi-squares test.
All other statistical significance was determined by one-way ANOVAwith post-
hoc Bonferonni tests. A p value of < 0.05 was considered statistically signifi-
cant. All results are presented as mean ± standard error of the mean (SEM).
SUPPLEMENTAL DATA
Supplemental Data include Results, Experimental Procedures, two tables, and
seven figures and can be found with this article online at http://www.cell.com/
cgi/content/full/133/3/462/DC1/.
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